asco.org4d
T-cell redirected bispecific antibodies in relapsed and refractory multiple myeloma: A systematic review and meta-analysis.
NR- not reported NR*- not reached Clinical outcome data with use of bispecific antibodies.
asco.org5d
Conflict of Interest (COI)
The American Society of Clinical Oncology (ASCO) is a professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient ...
asco.org6d
Funding Opportunities
Our grants and awards support basic, translational and clinical cancer research done by gifted physician-scientists at every stage of their careers, from the best and brightest among young ...
asco.org4d
ASCO's Advocacy Toolkit
The Association for Clinical Oncology (ASCO) offers multiple ways for you and your colleagues to engage with policymakers and educate them on ASCO’s advocacy priorities, while leveraging your insights ...
asco.org4d
Evolving patterns of transplant strategies for mantle cell lymphoma in the era of BTK inhibitors and CAR-T therapy.
83.3% (n=25) vs 6.7% (n=2) vs 10% (n=3) 21.8% (n=8) vs 15.6% (n=2) vs 59.3% (n=19) 44.4% (n=4) vs 11.1% (n=1) vs 44.4% (n=4) <0.001 ...
asco.org4d
Combination immunotherapy selection for non-PD-1 axis driven tumors.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org4d
Chemotherapy for metastatic colon cancer: Effect on survival when the dose is reduced due to side effects.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org4d
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org4d
Mental distress among adolescent and young adult (AYA) and adult cancer survivors.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org5d
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org5d
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org4d
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...